News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
FOSUN PHARMA Granted Exclusive Commercialization Option for Alzheimer's Disease Therapy
FOSUN PHARMA (02196.HK) announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial Development (Fosun Pharma Industrial), has been granted an exclusive opt...
Reset
Send
The window will close in 5 seconds
FOSUN PHARMA Granted Exclusive Commercialization Option for Alzheimer's Disease Therapy
Close
Recommend
2
Positive
2
Negative
3
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

FOSUN PHARMA (02196.HK)  +0.480 (+2.902%)    Short selling $5.47M; Ratio 8.869%   announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial Development (Fosun Pharma Industrial), has been granted an exclusive option by AriBio.

Pursuant to the agreement, upon completion of the global multi-center Phase III clinical trial of the licensed product for the treatment of early-stage Alzheimer's disease, AriBio shall provide Fosun Pharma Industrial with all top-line data. Fosun Pharma Industrial has the right to decide whether to exercise the exclusive option no later than 90 calendar days after receipt of such top-line data.

If the option is exercised, Fosun Pharma Industrial will obtain from AriBio exclusive rights on a global basis to develop, register, manufacture and commercialize the licensed product within the licensed field and territory, including but not limited to the United States, Europe and Japan, and will act as the marketing authorization holder for the product in those regions.

Under the agreement, Fosun is required to pay an option fee of USD60 million. Upon exercise of the option, it will pay an upfront payment of USD80 million and up to USD100 million in regulatory milestone payments, in addition to sales milestones and low double-digit sales royalties.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.